CClinicalTrials.gg
TerminatedNCT02026180Updated Jul 15, 2014

Micropuncture vs. Standard Common Femoral Artery Access

An interventional study of Micropuncture Access in Vascular Access Complications, sponsored by North Texas Veterans Healthcare System. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-15.

Sponsored by North Texas Veterans Healthcare System · Not applicable, Interventional, and Treatment

Why this study was terminated
low incidence of primary endpoint
Phase
Not applicable
Study type
Interventional
Enrollment
552
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Vascular access complications can occur during or after cardiac or peripheral arterial catheterization. These complications increase patient morbidity and mortality, as well as healthcare costs. Several strategies and devices have been employed to decrease the risk for vascular access complications, such as fluoroscopy-guided access, ultrasound-guided access and vascular closure devices. Randomized trial data has failed to demonstrate that fluoroscopic guidance reduces common femoral artery access complications. While meta-analysis data has demonstrated that vascular closure devices decrease time to arterial hemostasis, increase patient mobilization and facilitate earlier patient discharge, they do not reduce the incidence of vascular complications as compared to hemostasis achieved with manual pressure. Ultrasound guidance has been shown to facilitate femoral artery access and reduce femoral artery vascular complications. A new device, the Micropuncture Kit (Cook Medical, Bloomington, IN) allows vascular access with a small 21gauge needle as opposed to the standard method, which requires an 18 gauge needle. The use of the Micropuncture Kit for the purpose of decreasing vascular access complications has not been examined in a randomized study to date.

The present study is a 552 patient randomized controlled clinical trial that will help determine whether femoral arterial access obtained using the Micropuncture Kit will reduce the incidence of vascular access complications compared to the standard 18 gauge needle.

The specific aim of this proposal is to compare the rate of femoral artery access complications using the Micropuncture Kit vs. standard femoral artery access.

It is our hypothesis that the incidence of femoral artery access complications will be lower among patients in whom the Micropuncture Kit is used.

02

Conditions studied

  • Vascular Access Complications
03

In context

Lead sponsor

North Texas Veterans Healthcare System is the lead sponsor of 31 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Patients undergoing left heart or peripheral catheterization through the common femoral artery with anticipated or possible percutaneous coronary or peripheral intervention

Exclusion Criteria:

  1. Arterial access obtained through the radial or brachial artery
  2. Age less than 18 years
  3. Patients with known bleeding diathesis
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
552 participants (estimated)

Study arms

  • Active comparator
    Micropuncture Access

    Vascular access using micropuncture needle kit

    Device: Micropuncture Access

  • Active comparator
    Standard 18G vascular access needle

    Vascular access using standard 18G needle

    Device: Micropuncture Access

Interventions

  • DeviceMicropuncture Access

    Femoral arterial access will be obtained either with a 21G micropuncture needle kit or an 18G standard access needle.

06

What researchers measure

Primary outcomes

  1. Arterial perforation

    Time frame: 30 days

  2. Acute limb ischemia

    Acute limb ischemia, indicated by thrombosis or loss of distal pulses

    Time frame: 30 days

  3. Arteriovenous fistula

    Arteriovenous fistula, defined as an abnormal communication between an artery and a vein

    Time frame: 30 days

  4. Access site pseudoaneurysm

    Time frame: 30 days

  5. Retroperitoneal bleeding

    Retroperitoneal bleeding defined as computerized tomography confirmation of femoral artery hemorrhage into the retroperitoneal space

    Time frame: 30 days

  6. Groin hematoma

    Groin hematoma, defined as hematoma \>5 cm.

    Time frame: 30 days

  7. Femoral artery dissection

    Femoral artery dissection confirmed by angiography

    Time frame: 30 days

07

Study locations

1 site
  • Dallas VA Medical Center
    Dallas, Texas 75216, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02026180
Lead sponsor
North Texas Veterans Healthcare System
Responsible party
Emmanouil Brilakis (MD, PhD, North Texas Veterans Healthcare System) — Principal investigator
First posted
Jan 1, 2014
Start date
Dec 2013
Primary completion
Jun 2014
Last update
Jul 15, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion